SEC Form 4 · accession 0001225208-18-002886
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin J. Ballinger
Officer — EVP & Pres, Interven Cardio
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 5, 2018 | G | 375 | $0.00 | D | 71,151 | D | |
| Common StockF2,F1 | Feb 12, 2018 | A | 36,786 | $0.00 | A | 107,937 | D | |
| Common StockF1 | Feb 12, 2018 | F | 13,890 | $26.18 | D | 94,047 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Share UnitsF4,F3 | — | Feb 12, 2018 | A | 16,117 | A | Dec 31, 2019 | Dec 31, 2019 | Common Stock | 16,117 | 16,117 | D |
Explanation of responses
- F1Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F2On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2017 and was subject to the completion of the concurrent three-year individual service period. On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- F3Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- F4On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019.